NASDAQ:OCS Oculis (OCS) Stock Price, News & Analysis $11.95 -0.04 (-0.33%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$11.94▼$11.9850-Day Range$10.94▼$12.0952-Week Range$9.05▼$14.47Volume8,698 shsAverage Volume31,793 shsMarket Capitalization$484.02 millionP/E RatioN/ADividend YieldN/APrice Target$30.17 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get Oculis alerts: Email Address Oculis MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside152.4% Upside$30.17 Price TargetShort InterestHealthy0.08% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.27Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.07) to ($2.18) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.29 out of 5 starsMedical Sector696th out of 910 stocksPharmaceutical Preparations Industry326th out of 426 stocks 3.5 Analyst's Opinion Consensus RatingOculis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageOculis has only been the subject of 4 research reports in the past 90 days.Read more about Oculis' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.08% of the float of Oculis has been sold short.Short Interest Ratio / Days to CoverOculis has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Oculis has recently increased by 20.93%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldOculis does not currently pay a dividend.Dividend GrowthOculis does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for OCS. Previous Next 2.4 News and Social Media Coverage News SentimentOculis has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Oculis this week, compared to 2 articles on an average week.Search Interest3 people have searched for OCS on MarketBeat in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Oculis insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 22.30% of the stock of Oculis is held by institutions.Read more about Oculis' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Oculis are expected to decrease in the coming year, from ($2.07) to ($2.18) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Oculis is -6.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Oculis is -6.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOculis has a P/B Ratio of 3.88. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Oculis' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. About Oculis Stock (NASDAQ:OCS)Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.Read More OCS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OCS Stock News HeadlinesSeptember 1, 2024 | americanbankingnews.comOculis Holding AG (NASDAQ:OCS) Short Interest UpdateAugust 31, 2024 | americanbankingnews.comResearch Analysts Set Expectations for Oculis Holding AG's Q3 2024 Earnings (NASDAQ:OCS)September 7, 2024 | Weiss Ratings (Ad)“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.August 30, 2024 | markets.businessinsider.comOptimistic Buy Rating for Oculis Holding Amidst Clinical and Regulatory ProgressAugust 30, 2024 | finance.yahoo.comOculis Holding (NASDAQ:OCS) Is In A Good Position To Deliver On Growth PlansAugust 29, 2024 | americanbankingnews.comOculis Holding AG (NASDAQ:OCS) to Post Q1 2025 Earnings of ($0.49) Per Share, HC Wainwright ForecastsAugust 29, 2024 | americanbankingnews.comOculis (NASDAQ:OCS) Receives Buy Rating from HC WainwrightAugust 29, 2024 | globenewswire.comOculis to Present at Upcoming September Investor ConferencesSeptember 7, 2024 | Weiss Ratings (Ad)“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.August 28, 2024 | americanbankingnews.comOculis (OCS) Set to Announce Earnings on TuesdayAugust 27, 2024 | msn.comOculis files to sell 361,011 ordinary shares for holdersAugust 27, 2024 | globenewswire.comOculis Publishes Consolidated Q2 Financial Statements and MD&AAugust 27, 2024 | globenewswire.comOculis Reports Q2 Financial Results and Provides Recent Company UpdateAugust 27, 2024 | globenewswire.comOculis Reports Q2 2024 Financial Results and Provides Recent Company UpdateAugust 15, 2024 | markets.businessinsider.comOculis Appoints Sharon Klier, M.D., M.S., M.P.H. as Chief Development OfficerAugust 1, 2024 | seekingalpha.comOCS Oculis Holding AGJuly 30, 2024 | globenewswire.comOculis to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual ConferenceJuly 25, 2024 | msn.comOculis’ (OCS) Stock Moves Sideways Amid Growing AnticipationSee More Headlines Receive OCS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oculis and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today9/07/2024Next Earnings (Estimated)11/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:OCS CUSIPN/A CIK1953530 Webwww.oculis.com Phone41-21-711-3970FaxN/AEmployees2Year FoundedN/APrice Target and Rating Average Stock Price Target$30.17 High Stock Price Target$37.00 Low Stock Price Target$20.00 Potential Upside/Downside+152.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.78) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-98,920,000.00 Net Margins-7,679.05% Pretax Margin-10,040.34% Return on Equity-61.33% Return on Assets-49.91% Debt Debt-to-Equity Ratio0.01 Current Ratio5.27 Quick Ratio4.71 Sales & Book Value Annual Sales$980,000.00 Price / Sales493.90 Cash FlowN/A Price / Cash FlowN/A Book Value$3.08 per share Price / Book3.88Miscellaneous Outstanding Shares40,504,000Free FloatN/AMarket Cap$484.02 million OptionableNot Optionable Beta0.30 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. Riad Sherif M.B.A. (Age 56)M.D., CEO & Director Ms. Sylvia Cheung (Age 49)Chief Financial Officer Dr. Ramin Tadayoni M.D.Ph.D., Chief Scientific OfficerMs. Virginia R. Dean (Age 57)Chief Human Resources Officer Dr. Bastian Dehmel M.D. (Age 53)Chief Development Officer Mr. Páll Ragnar Jóhannesson (Age 42)Chief Business Officer Ms. Rebecca WeilChief Commercial OfficerDr. Snehal Shah Pharm.D.President of Research & DevelopmentMore ExecutivesKey CompetitorsIntellia TherapeuticsNASDAQ:NTLAKeros TherapeuticsNASDAQ:KROSAkero TherapeuticsNASDAQ:AKROGalapagosNASDAQ:GLPGKiniksa PharmaceuticalsNASDAQ:KNSAView All Competitors OCS Stock Analysis - Frequently Asked Questions How have OCS shares performed this year? Oculis' stock was trading at $11.23 at the start of the year. Since then, OCS shares have increased by 6.4% and is now trading at $11.95. View the best growth stocks for 2024 here. How do I buy shares of Oculis? Shares of OCS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:OCS) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oculis Holding AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Oculis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
